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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of ERT in people with LOPD.
B A C K G R O U N D
Description of the condition
Pompe disease, also known as glycogen storage disease type 2
(OMIM 232300), is an autosomal recessive disease caused by
a deficiency of the enzyme acid alpha-glucosidase (GAA) (EC
3.2.1.20). This enzyme is responsible for the degradation of lyso-
somal glycogen by hydrolysis of alpha-1,4 and alpha-1,6 links
of glycogen (Hirschorn 2001). The loss of GAA enzyme activity
causes an accumulation of lysosomal glycogen leading to cellular
dysfunction. Muscle biopsy reveals glycogen within the lysosomes,
free glycogen and periodic acid Schiff (PAS)-positive vacuolation
within the muscles. Estimates of the incidence of GAA deficiency
range from 1 in 8686 in an Austrian study of combined early- and
later-onset Pompe disease (Mechtler 2012), to 1 in 40,000 in a
study from the Netherlands (Ausems 1999).
More than 300 variants in theGAA gene have been identified. The
mutations include the entire range of genetic defects (i.e. missense,
nonsense, large and small insertions and deletions, and frame-
shift mutations). There is generally a good correlation between the
nature of the mutation, the degree of residual enzyme activity and
the severity of the clinical presentation.
Those with infantile-onset disease have either a complete or a near-
complete enzyme deficiency (Hirschorn 2001), while people with
late-onset Pompe disease (LOPD) retain some residual enzyme
activity. There is thus an inverse correlation between residual en-
zyme activity and disease severity (van der Ploeg 2008). LOPD
displays a less severe, but progressive phenotype, with skeletal
muscle weakness and respiratory complications occurring later in
life. In contrast, those with infantile-onset Pompe disease (classic
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and non-classic forms) typically present in early infancy with car-
diomyopathy and muscular hypotonia, which in untreated cases
rapidly leads to cardiorespiratory failure and death in the first year
of life (Kishnani 2006). The non-classic infantile forms present
with slower progressive cardiac and respiratory involvement, and
death occurs in later infancy or early childhood.
In those with LOPD, GAA deficiency can present at any age
through childhood, adolescence or adulthood. In a study from the
Netherlands, the mean age of presentation was 28 years, however,
18% presented at under 12 years of age (Hagemans 2005). Prog-
nosis at a given point is dependent on the time since diagnosis
rather than age.
The first clinical presentation of LOPD in childhoodmay be insid-
ious. Children under 12 months of age with no cardiomyopathy,
and those between 12 months and 12 years, present with proximal
muscle weakness (upper limbs and trunk), scoliosis, developmen-
tal delay, delayed motor milestones, and shortness of breath after
exercise. Children over 12 years of age present with proximal mus-
cle weakness (hips and lower limbs), ambulatory difficulties, loss
of ability to run, difficulty walking upstairs, distal muscle weak-
ness (lower), shortness of breath after exercise and hypotonia. Di-
agnosis of children who present with musculoskeletal symptoms
after the age of 12 months is frequently delayed (Kishnani 2006;
van den Hout 2003). Elevated creatine kinase may be the first
abnormal biochemical finding before the onset of muscle disease
(Pellegrini 2005).
Children with LOPD may retain the ability to walk into adult-
hood, but have a raised risk of respiratory failure, as muscle weak-
ness often particularly affects the diaphragm (Kishnani 2013).
Specifically, the capacity to generate tidal volume gradually de-
creases with respiratory muscle weakness (Mah 2010). In a registry
analysis, shortness of breath after exercise was the only respiratory
symptom in LOPD and was noted in 11% to 20% of children
aged between 12 months and 16 years of age (Kishnani 2013).
Those presenting in adulthood commonly experience initial im-
pairment of hip flexors followed by progressive proximal weakness
in a limb-girdle distribution (Beltran Papsdorf 2014). The heart
is not involved in LOPD, but respiratory symptoms are signifi-
cant, with diaphragmatic involvement leading to respiratory im-
pairment (Amato 2011).With progressive decline of critical respi-
ratorymuscle function, especially the diaphragm, sleep-disordered
breathing arises with associated symptoms of morning headache,
daytime somnolence and fatigue (Johnson 2016). Without treat-
ment there is invariably a decline in muscle function and respi-
ratory insufficiency, however, the rate and predominance of mo-
tor weakness or respiratory failure is heterogeneous. Non-invasive
nocturnal ventilation may be required for nocturnal hypoxia, with
some individuals progressing to invasive ventilation. The addition
of ventilatory support or wheelchair use are significant events in
disease progression, reducing quality of life and survival. Estimated
survival at five years following diagnosis is 95% and at 30 years
following diagnosis is 40% (Tein 1996).
The care provided to people with Pompe disease is often deliv-
ered by a multidisciplinary team with input from a neurologist,
respiratory physician, physiotherapist, occupational therapy, dieti-
tian and speech and language therapist, in addition to a specialist
metabolic physician.
Description of the intervention
GAA deficiency is treated by intravenous infusion of recombinant
alglucosidase alfa, an enzyme replacement therapy (ERT). This
was approved by the Food and Drug Administration in 2006 for
people with infantile-onset Pompe disease and subsequently for
LOPD. Alglucosidase alfa (commercial name Myozyme, previ-
ously known as Lumizyme) is produced in Chinese hamster ovary
cells by recombinant DNA technology. The recommended dose
regimen of alglucosidase alfa is 20 mg/kg of body weight admin-
istered once every two weeks. It comes as a lyophilised powder in
a vial, which is reconstituted prior to infusion. One vial contains
50 mg of alglucosidase alfa. It is recommended that the infusion
begins at an initial rate of 1 mg/kg per hour and gradually be in-
creased by 2 mg/kg per hour every 30 minutes if there are no signs
of infusion-associated reactions (IARs) until a maximum rate of
7 mg/kg per hour is reached. The treatment is immunogenic and
can lead to anaphylactic and other immune-mediated reactions
(EMA 2011).
How the intervention might work
It is postulated that alglucosidase alfa replaces the missing or de-
ficient lysosomal GAA, producing stabilisation or restoration of
cardiac, respiratory muscle and skeletal muscle function. Pharma-
cokinetic studies are similar in infants and adults, and show amean
plasma elimination half-life (t1/2) of between two to three hours
that does not change over time.
Why it is important to do this review
This review is designed to critically evaluate the available evidence
on the efficacy and safety of ERT for treating LOPD. Given that
LOPD is a very rare and slow progressive disease, it is not always
possible to gather class I evidence or to conduct randomized clini-
cal trials. This review, however, may answer some of the questions
surrounding ERT for treating LOPD and help in clinical practice.
O B J E C T I V E S
To assess the effects of ERT in people with LOPD.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include any randomized controlled trials (RCTs) or quasi-
RCTs.
Types of participants
Children and adults with a confirmed diagnosis of LOPD made
by GAA level. Individuals may also have identified pathogenic
mutations and characteristic muscle histology and enzymology.
Wewill not include studies that explore only infantile-onset Pompe
disease, although it is possible that paediatric studies will include
both infantile- and late-onset individuals; in such cases, we will
try to obtain outcome data for those with the late-onset disease.
Types of interventions
Any ERT for treating LOPD. Currently, there is only one licensed
ERT (Myozyme) for this condition (EMA 2011).
We will compare the following active interventions to each other:
1. ERT versus placebo;
2. ERT alone versus ERT with an adjuvant therapy (e.g. diet
and exercise);
3. ERT alone versus ERT with a chaperone therapy (currently
in clinical trial phase);
4. different dosing regimens.
Types of outcome measures
Primary outcomes
1. Six-minute-walk test (6MWT)
2. Respiratory function (as assessed by per cent (%) predicted
forced vital capacity (FVC), % predicted forced expiratory
volume in one second (FEV1) and sniff nasal inspiratory pressure
(SNIP))
3. Infusion reactions
Secondary outcomes
1. Need for respiratory support (non-invasive or invasive)
i) number of participants
ii) duration
2. Use of a walking aid* or wheelchair
3. Quality of life (QoL) (as measured by validated
questionnaires, e.g. SF-36, EQ-5D and for children the PedsQL)
4. Treatment- or disease-related adverse events
* walking aids will be characterised as use of: a single stick, two
sticks, furniture for support, a wheelchair only when outdoors, or
a wheelchair in the house and outdoors.
Search methods for identification of studies
We will search for all relevant published and unpublished trials
without restrictions for language, year or publication status.
Electronic searches
Wewill identify relevant studies from theCochraneCystic Fibrosis
andGeneticDisordersGroup’s InbornErrors ofMetabolismTrials
Register using the search term: Pompe Disease.
The Inborn Errors of Metabolism Trials Register is compiled from
electronic searches of the Cochrane Central Register of Controlled
Trials (CENTRAL) (updated with each new issue of the Cochrane
Library), weekly searches ofMEDLINE and the prospective hand-
searching of one journal - Journal of Inherited Metabolic Disease.
Unpublished work is identified by searching through the abstract
books of the Society for the Study of Inborn Errors of Metabolism
conference and the SHS Inborn Error Review Series. For full de-
tails of all searching activities for the register, please see the rele-
vant section of Cochrane Cystic Fibrosis and Genetic Disorders
Group’s website.
We will search the following databases and trials registries:
1. MEDLINE OvidSP (1946 - present);
2. US National Institutes of Health Ongoing Trials Register
Clinicaltrials.gov (www.clinicaltrials.gov);
3. the World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP) (apps.who.int/trialsearch).
For full details of our search strategies, please see Appendix 1.
Searching other resources
We will attempt to identify relevant trials using the following
methods.
1. Checking reference lists of review articles, relevant studies
and clinical practice guidelines.
2. Sending letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
3. Handsearching of metabolic journals and proceedings from
major metabolic and lysosomal storage diseases (LSD)
conferences. They will be searched from 2000 onwards until one
year prior to completion of the review.
4. Reading weekly current awareness alerts that will include
Rare Disease Report and Lysosomal Disease Network alerts.
For full details of resources to be hand searched, please see
Appendix 2.
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Data collection and analysis
Selection of studies
Two authors will conduct an initial sift of the search results to
identify potentially relevant articles. To determine the studies for
further assessment, at least two review authors, independently, will
scan the abstract, title or both, of the selected records. The authors
will review the full text (if available) of all potentially relevant
articles.
If there are any differences in opinion, the review authors will re-
solve these by consensus or, if necessary, with an independent ad-
visor. If it is not possible to resolve a disagreement regarding study
selection, the review authors will add the article to those ’Awaiting
assessment’ and contact the study investigators for clarification.
The review authors will include a PRISMA diagram to show the
flow of study selection.Where relevant, the authors will seek trans-
lation of studies reported in non-English language journals before
assessment.
Data extraction and management
At least two authors will extract data using a customised version
of the Cochrane Cystic Fibrosis and Genetic Disorders Review
Group’s study selection, quality assessment and data extraction
form. They will record the following information.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline characteristics,
inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
They will measure inter-rater agreement for study selection using
the kappa statistic (Cohen 1960). If there are any differences in
opinion, the review authors will resolve these by consensus or, if
necessary, with an independent advisor.
We plan to group outcome data into those measured at up to
6 months, over 6 months to 12 months, over 12 months to 18
months, over 18 months to 2 years, etc. If outcome data are
recorded at other time periods, we will consider examining these
as well.
Assessment of risk of bias in included studies
At least two authors will independently assess the risk of bias for
each study. They will use the Cochrane ’Risk of bias’ tool to as-
sess various criteria in the selected studies in line with methods
described in the Cochrane Handbook of Systematic Reviews of Inter-
ventions (Higgins 2011a). This approach uses risk of bias tables,
where each study is assessed according to the following bias do-
mains.
1. Sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of assessment
5. Incomplete outcome data
6. Incomplete reporting
7. Other risks of bias
The authors will assess each domain as having a low, high, or
unclear risk of bias. They will then classify each study’s overall risk
as bias follows.
1. Low risk (if all domains are assessed as low risk)
2. Moderate risk (if one or more domains is assessed as unclear
risk)
3. High risk (if one or more domains is assessed as high risk)
Three review authors will meet to agree the risk of bias for each
study. If there is disagreement, the authors will ask a fourth author
for an opinion and to adjudicate on the result.
Measures of treatment effect
The authors anticipate the review will involve analysis of dichoto-
mous as well as continuous data.
For continuous data (e.g. 6MWT, pulmonary function tests, QoL
scoring), the authors will use the mean and standard deviation
(SD) to calculate the mean difference (MD) with corresponding
95% confidence intervals (CIs). The authors aim to report change
from baseline.
Where outcome data are skewed, the authors will consider using
approximations to calculate the mean on the log scale using one
of the methods proposed by Higgins (method 1) (Higgins 2008).
Where the data are dichotomous (e.g. infusion reactions, the need
for respiratory support, use of walking aid or wheelchair, adverse
events), the authorswill calculate the treatment effect using the risk
ratio (RR) and the relative risk difference (RD)with corresponding
95% CIs.
For individual adverse events we will consider using 99% CIs to
avoid type I errors from multiple statistical testing.
Unit of analysis issues
As stated in Data extraction and management, results may be
presented for several periods of follow-up and data frommore than
one time point for each study cannot be combined in a standard
meta-analysis without causing a unit-of-analysis error. The authors
will consider which of the options (for repeated observations on
participants) suggested in chapter nine of the Cochrane Handbook
for Systematic Reviews of Interventions they will implement for data
analysis (Deeks 2011).
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It is possible that studies may compare multiple intervention
groups and the authors will treat these with care, as this can poten-
tially lead to unit-of-analysis problems if the same group of partic-
ipants is counted twice. The authors will aim to combine groups
to create a single pair-wise comparison, but if this is not possible,
they will follow the guidance in chapter 16 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011b).
The authors will resolve any special issues arising from the analysis
of included studies with a non-standard design as per guidance
from the Cochrane Cystic Fibrosis and Genetic Disorders Group.
Dealing with missing data
The authors will make every effort to obtain any missing infor-
mation or data for the included studies (including contacting the
study authors) in line with guidance from theCochrane Hand-
book for Systematic Reviews of Interventions, and will document any
methods they use to deal with missing data in the review (Higgins
2011b).
Assessment of heterogeneity
The authors will assess heterogeneity using the I² statistic, which
gives insight into the level of variability within results that is due
to heterogeneity rather than chance alone (Higgins 2003). The
authors will assess heterogeneity in terms of overlapping percent-
age intervals. The values of I² lie between 0% and 100%, and a
simplified categorisation of heterogeneity that the authors plan to
use is (Higgins 2011):
1. 0% to 40%: might not be important;
2. 30% to 60%: may represent moderate heterogeneity;
3. 50% to 90%: may represent substantial heterogeneity;
4. 75% to 100%: may represent considerable heterogeneity.
However, the authors acknowledge that closer investigation of the
consistency of the direction and strength of the effect in studies is
helpful and gives a better interpretation of I² (Higgins 2003).
Assessment of reporting biases
In an effort to address reporting bias, the literature search will be as
comprehensive as possible to prevent missing any eligible studies.
The authors will also search trials registers for this purpose. The
authors plan to construct a funnel plot only if they include 10
or more studies in the review. If asymmetry occurs, the authors
will consider whether this provides evidence of small-study effects
and publication bias (Sterne 2011). The authors will address the
potential impact of reporting bias on the review’s findings in the
’Discussion’ section of the final review.
Data synthesis
The authors will follow this Cochrane Review protocol to inte-
grate the evidence generated for any available qualitative or quan-
titative data. They will consider the robustness of the estimated
treatment effects of the included publications by undertaking sen-
sitivity analyses based on the methodology used and the type of
publication. They will summarize studies in a tabular form fol-
lowing the GRADE approach (Schünemann 2011a; Schünemann
2011b).
The authors will compute pooled estimates of the treatment effect
for each outcome using a fixed-effect model. However, for out-
comes where they identify a substantial or considerable level of
heterogeneity, they plan to use a random-effects model, as recom-
mended in chapter nine of the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011).
Subgroup analysis and investigation of heterogeneity
If at least moderate heterogeneity (as defined above) is present, the
authors plan to conduct subgroup analyses based on participant
age, that is children (younger than 18 years of age), adults (18
years and older), and elderly adults (65 years and older), within the
different intervention categories. In addition to this, since symp-
tom duration may affect responsiveness of therapy, we also plan
to conduct subgroup analyses on the basis of length of duration
of disease symptoms.
Sensitivity analysis
If the authors find data are incomplete, or if they need to impute
data, or if criteria limits are poorly defined (such as age ranges, or
what constitutes ’standard care’) they plan to undertake sensitivity
analyses. They will complete the meta-analyses with and without
the contentious data, to assess its impact upon the overall find-
ings. If the results of the meta-analysis are not greatly altered, the
robustness of the review increases. If the results of the two analyses
differ greatly, then the results of the review should be interpreted
with caution.
If the authors identify different levels of potential bias in the stud-
ies, they will conduct sensitivity analyses. If they judge that some
studies contain potentially high or unclear levels of bias, they will
omit these from the analyses. This again allows the authors to iden-
tify the impact of these studies upon the results of the analyses. If
there is no marked difference in results due to this omission, this
will strengthen the conclusions of the review by indicating that
the the results are not affected by the potential bias of the studies.
If any heterogeneity cannot be explained by the prespecified sub-
group analyses, the authors will perform a sensitivity analysis using
a random-effects model.
’Summary of findings’ table
We will use the GRADE approach to create a ’Summary of find-
ings’ (SoF) table, as suggested in chapters 11 and12of theCochrane
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Handbook for Systematic Reviews of Interventions (Schünemann
2011a; Schünemann 2011b). We will used the GRADE approach
to rate the quality of the evidence as ’high’, ’moderate’, ’low’, or
’very low’ using the five GRADE considerations.
1. Risk of bias: serious or very serious
2. Inconsistency: serious or very serious
3. Indirectness: serious or very serious
4. Imprecision: serious or very serious
5. Publication bias: likely or very likely
We will report separate SoF tables for all the outcome measures
mentioned in the primary and secondary endpoints earlier. Each
SoF table will be generated for each comparison listed below.
1. 6MWT
2. Overview of respiratory function (as assessed by %
predicted FVC, % predicted FEV1 and SNIP)
3. Infusion reactions
4. Need for respiratory support (non-invasive)
5. Use of a walking aid or wheelchair
6. QoL score
7. Overview of disease- or treatment-related adverse events
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A P P E N D I C E S
Appendix 1. Search methods - electronic searches
Database/ Resource Strategy
MEDLINE OvidSP (1946 - present) #1 Glycogen Storage Disease Type II/
#2 (glycogen storage disease adj2 (type 2 or type II)).tw.
#3 pompe disease.tw.
#4 1 or 2 or 3
#5 Enzyme Replacement Therapy/
#6 (enzyme* adj2 replac*).tw.
#7 (alglucosidase or myozyme or lumizyme or genzyme).tw.
#8 5 or 6 or 7
#9 4 and 8
#10 ((late or adult) adj3 onset).tw.
#11 9 and 10
#12 randomized controlled trial.pt.
#13 controlled clinical trial.pt.
#14 randomized.ab.
#15 placebo.ab.
#16 drug therapy.fs.
#17 randomly.ab.
#18 trial.ab.
#19 groups.ab.
#20 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
#21 (animals not (humans and animals)).sh.
#22 20 not 21
#23 11 and 22
NOTE: Lines #12- #22 are the Cochrane Highly Sensitive Search Strategy for identifying
randomized trials inMEDLINE: sensitivity-maximizing version (2008 revision);Ovid format
Clinicaltrials.gov [Advanced Search Form]
OTHER TERMS: alglucosidase OR myozyme OR lumizyme OR genzyme OR enzyme*
STUDY TYPE: Interventional Studies
CONDITION/ DISEASE: Pompe disease OR glycogen storage disease OR LOPD
WHO ICTRP [Advanced Search]
CONDITION: Pompe disease OR glycogen storage disease OR LOPD
INTERVENTION: alglucosidase OR myozyme OR lumizyme OR genzyme OR enzyme*
RECRUITMENT STATUS: All
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Appendix 2. Search methods - handsearching
The following conference proceedings will be searched from 2000 onwards until one year prior to completion of the review.
1. SSIEM (Society for the Study of Inborn Errors of Metabolism) International Conference (2000 onwards).
2. Lysosomal Disease Network Annual WORLD Symposium (2000 onwards).
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